Abstract
Abstract 5186
Beta Thalassemia (β-thalassemia) is one of the more common hemoglobinopathies worldwide, being the heterozygous variant, called Beta Thalassemia Trait, a benign variant, but important to diagnose, for genetic counseling, trying to avoid the homozygous variant, called major.
Classic testing for β-thalassemia includes: hematologic testing of red blood cell indices, peripheral blood smear (prewsence of target cells and RBC with basophilic stippling, etc.), and qualitative and quantitative hemoglobin analysis. Have been proposed too Discriminant functions, like the one published many years ago, by England and Fraser.
Recently have been developed new parameters and information in the new automated hematology analyzer called DxH8008™ from Beckman Coulter as @MSCV, @RSF, @MAF, @ LHD% and many morphological parameters for RBC and Reticulocytes calles Cell Population Data. All this parameters may be used to create flagging for laboratory use only (LUO) or Research use only (RUO). The purpose of this study is to investigate the possible use or utility of this new information for the screening/flagging of Beta Thalassemia Trait.
We have collected 30 patients with Beta Thalassemia Trait. All of them were confirmed by red cell morphology, Hgb Electroforesis, cromatography in liquid phase in human whole blood for the determination of Hemoglobin A2, F, A1c, and identification of abnormal hemoglobins and DNA analysis (DNA Analysis by GAP-PCR). We have compared these patients with a control group (184 individuals) and with other anemias (see Table 1).
Diagnostic . | n . |
---|---|
NON BETA (control) | 184 |
HbH (alfa thalasemia intermedia) | 129 |
Alfa Thalassemia Heterozygous | 48 |
Beta Thalassemia Trait (study group) | 30 |
Hereditary Spherocytosis | 28 |
Iron Deficiency Anaemia | 22 |
Thalassemia intermedia (Beta-Thal Interm) | 18 |
microdrepanocitosi (Beta-S) | 8 |
Blackfan-Diamond Anemia | 3 |
Dyserithropoietic Anaemia type I (CDA I) | 3 |
Sickle cell anaemia | 3 |
Piruvate-Kinase deficiency | 3 |
IRIDA iron-refractory iron deficiency anemia | 3 |
Fanconi's Anaemia | 2 |
Dyserithropoietic Anaemia type II (CDA II) | 2 |
Hyporegenerative anemia | 2 |
Megaloblastic Anemia | 1 |
Piruvate-Kinase deficiency Splenectomized | 1 |
Hemoglobinopaty (Taybe) + α-thalassemia | 1 |
Hemoglobinopaty hyperunstable (Hb Cagliari) | 1 |
Hemoglobinopaty Koln | 1 |
Acute Lymphoblastic Leukemia (ALL) | 1 |
Pyropoikilocytosis | 1 |
Evans's Syndrome | 1 |
Diagnostic . | n . |
---|---|
NON BETA (control) | 184 |
HbH (alfa thalasemia intermedia) | 129 |
Alfa Thalassemia Heterozygous | 48 |
Beta Thalassemia Trait (study group) | 30 |
Hereditary Spherocytosis | 28 |
Iron Deficiency Anaemia | 22 |
Thalassemia intermedia (Beta-Thal Interm) | 18 |
microdrepanocitosi (Beta-S) | 8 |
Blackfan-Diamond Anemia | 3 |
Dyserithropoietic Anaemia type I (CDA I) | 3 |
Sickle cell anaemia | 3 |
Piruvate-Kinase deficiency | 3 |
IRIDA iron-refractory iron deficiency anemia | 3 |
Fanconi's Anaemia | 2 |
Dyserithropoietic Anaemia type II (CDA II) | 2 |
Hyporegenerative anemia | 2 |
Megaloblastic Anemia | 1 |
Piruvate-Kinase deficiency Splenectomized | 1 |
Hemoglobinopaty (Taybe) + α-thalassemia | 1 |
Hemoglobinopaty hyperunstable (Hb Cagliari) | 1 |
Hemoglobinopaty Koln | 1 |
Acute Lymphoblastic Leukemia (ALL) | 1 |
Pyropoikilocytosis | 1 |
Evans's Syndrome | 1 |
Using ROC analysis, the best parameters differentiating the Beta Thalassemia Trait from the normals were: MCV (AUC 1. 000), MRV (AUC 0. 999), @MAF(AUC 0. 999), @MCNRET (AUC 0. 997), RDW (AUC 0. 957), HGB (AUC 0. 915), RBC(AUC 0. 912).
Using ROC analysis, the best parameters differentiating the Beta Thalassemia Trait from other anemias (excluding normals) were: RDW-SD (AUC 0. 937), DF Eng-Fra (AUC 0. 779), RDW (AUC 0. 766), RBC (AUC 0. 734)
Simon-Lopez:Beckman Coulter: @LHD, @MAF, @RSF, @LHD, @MAF, @RSF Patents & Royalties, Employment. Di Gaetano:Instrumentation Laboratory spa: Work for a distributor of Beckman Coulter Instruments in Italy Other. Galanello:Ferrokin: Research Funding; Apopharma: Research Funding, Speakers Bureau; Novartis: Research Funding, Speakers Bureau.
Author notes
Asterisk with author names denotes non-ASH members.